Table 2.
Characteristics of included patients with central retinal vein occlusion stratified according to the final snellen visual acuity (≥ 20/200 and < 20/200).
| All (n = 150) | Control group (n = 101) | Very poor VA group (n = 49) | P value | |
|---|---|---|---|---|
| Sex (men/women) | 97/53 | 63/38 | 34/15 | 0.399 |
| Age (years) | 69.2 ± 12.8 | 67.2 ± 13.3 | 73.4 ± 10.4 | 0.002 |
| Duration of symptoms (weeks) | 6.8 ± 11.8 | 5.4 ± 7.2 | 8.8 ± 17.5 | 0.193 |
| Observation period (months) | 34.9 ± 16.1 | 32.9 ± 16.9 | 35.4 ± 18.3 | 0.467 |
|
Baseline logMAR BCVA (Snellen equivalent) |
0.67 ± 0.54 (HM to 20/13) |
0.54 ± 0.45 (20/2000 to 20/13) |
0.93 ± 0.61 (HM to 20/25) |
< 0.001 NA |
| Baseline CRT (µm) | 656 ± 255 | 641 ± 229 | 691 ± 314 | 0.287 |
|
Final logMAR BCVA (Snellen equivalent) |
0.60 ± 0.67 (NLP to 20/13) |
0.24 ± 0.33 (20/200 to 20/13) |
1.31 ± 0.57 (NLP to 20/228) |
< 0.001 NA |
| Final CRT (µm) | 329.3 ± 171.8 | 304.9 ± 149.4 | 338.2 ± 231.9 | 0.367 |
| Number of anti-VEGF injections | 5.3 ± 3.7 | 5.4 ± 3.4 | 5.2 ± 4.2 | 0.765 |
Data are expressed as mean ± standard deviation unless otherwise indicated.
BCVA best-corrected visual acuity, logMAR logarithm of the minimum angle of resolution, HM hand motion, NLP no light perception, NA not applicable, CRT central retinal thickness, VEGF vascular endothelial growth factor.